tirzepatide fda shortage says years-long is resolved, will give limited leeway to compounders FDA Ends Tirzepatide Shortage and

Early evidence suggests that it may also have a beneficial effect for people with Crohns disease

Several factors specific to combination format: Divergent optimal conditions

Witschi A, Reddy S, Stofer B, Lauterburg BH (1992)

A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes